



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

### Complete if Known

Application Number 10/829,674  
Filing Date April 22, 2004  
First Named Inventor Anna Helgadottir  
Art Unit 1634  
Examiner Name Not Yet Assigned  
Attorney Docket Number 30847/2048-004

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JG/	A1	US-2002/0107276	08/08/2002	Isakson et al.	
	A2	US-2003/0194721	10-16-2003	Mikita et al.	
	A3	US-2003/0225155	12-04-2003	Fernandez-Pol et al.	
	A4	US-2004/0053983-A1	03-18-2004	Barvian et al.	
	A5	US-2004/0014759	01-22-2004	Picard et al.	
	A6	US-4,970,215	11-13-1990	Mohrs et al.	
	A7	US-5,059,609	10-22-1991	Eggler et al.	
	A8	US-5,298,512	03-29-1994	Eggler et al.	
	A9	US-5,306,820	04-26-1994	Decker et al.	
	A10	US 5,527,827	06-18-1996	Delorme et al.	
	A11	US 5,576,338	11-19-1996	Friesen et al.	
	A12	US-5,641,789	06-24-1997	Marfat, A.	
	A13	US-5,939,529	08-17-1999	Potempa, L.	
	A14	US-5,981,559	11-09-1999	Nagaoka et al.	
	A15	US-5,990,148	11-23-1999	Isakson et al.	
	A16	US-6,166,031	12-26-2000	Eggler et al.	
	A17	US-6,436,924	08-20-2002	Poppe et al.	
	A18	US-6,521,747	02-18-2003	Anastasio et al.	
	A19	US-6,531,279	03-11-2003	Blumenfeld et al.	
	A20	US-6,797,475	09-28-2004	Barnes et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	CA 2337571	08-20-2002	Asta Medica AG		
	B2	DE 100 07203	08-23-2001	Asta Medica AG		
	B3	DE 4118014	12-03-1992	Rhone-Paulenc Rorer GmbH		
	B4	DE 4118173	12-10-1992	Rhone-Poulenc Rorer GmbH		
	B5	DE 4127842	02-25-1993	Rhone-Poulenc Rorer GmbH		
	B6	EP 0 344 519-B1	04-14-1993	Bayer AG		
	B7	EP 0 360 246	03-28-1990	G.D. Searle & Co.		
	B8	EP 0 509 359-B1	02-28-1996	Bayer AG		
	B9	EP 0 703 216	03-27-1996	ONO Pharmaceutical Co., Ltd.		
	B10	EP 0 870 762	10-14-1998	Santen Pharmaceutical Co., Ltd		
	B11	EP 0 947 502	10-06-1999	Santen Pharmaceutical Co., Ltd.		
	B12	JP 00355551	12-26-2000	Nikken Chemicals Co. Ltd.		
	B13	WO 94/00420	01-06-1994	The Scripps Research Institute		
	B14	WO 96/11192	04-18-1996	G.D. Searle & Co.		
	B15	WO 96/27585	09-12-1996	Santen Pharmaceutical Co., Ltd.		
	B16	WO 96/41625	12-27-1996	G.D. Searle & Co.		
	B17	WO 97/29774	08-21-1997	G.D. Searle & Co.		
	B18	WO 97/29775	08-21-1997	G. D. Searle & Co.		
	B19	WO 98/09943	03-12-1998	Santen Pharmaceutical Co., Ltd.		

Examiner Signature /Jeanine Goldberg/ Date Considered 10/20/2008

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,674
				Filing Date	April 22, 2004
				First Named Inventor	Anna Helgadottir
				Art Unit	1634
				Examiner Name	Not Yet Assigned
Sheet	2	of	8	Attorney Docket Number	30847/2048-004

B20	WO 98/13347	04-02-1998	Novartis AG		
B21	WO 98/40354	09-17-1998	G.D. Searle & Co.		
B22	WO 98/40364	09-17-1998	G.D. Searle & Co.		
B23	WO 98/40370	09-17-1998	G.D. Searle & Co.		
B24	WO 98/42345	10-01-1998	Eli Lilly and Company		
B25	WO 98/43954	10-08-1998	Santen Pharmaceutical Co., LTD.		
B26	WO 00/43001	07-27-2000	British Biotech Pharmaceuticals LTD.		
B27	WO 00/50577	08-31-2000	Jesper Z. Haeggstrom		
B28	WO 00/59864	10-12-2000	Institut Natl. De La Sante Et De LaRecherche Medicale		
B29	WO 01/34199	05-17-2001	Eli Lilly and Company		
B30	WO 01/57025	08-09-2001	Pfizer Products Inc.		
B31	WO 01/96347	12-20-2001	Bristol-Myers Squibb Company		
B32	WO 02/05825	01-24-2002	Bristol-Myers Squibb Company		
B33	WO 02/060378	08-08-2002	Ni-Tromed, Inc.		
B34	WO 03/037349	05-08-2003	Merck Patent GMBH		
B35	WO 03/063781	08-07-2003	Merck & Co., Inc.		
B36	WO 03/082191	10-09-2003	Merck & Co., Inc.		
B37	WO 03/086282	10-23-2003	Ni-Tromed, Inc.		
B38	WO 03/103602	12-18-2003	Ni-Tromed, Inc.		
B39	WO 2004/002409	01-08-2004	Ni-Tromed, Inc.		
B40	WO 2004/0047648	06-10-2004	Gary Tsaur		
B41	WO 2004/012686	02-12-2004	Ni-Tromed, Inc.		
B42	WO 2004/024186	03-25-2004	Ni-Tromed, Inc.		
B43	WO 2004/035741	04-29-2004	Decode Genetics EHF		
B44	WO 2004/052839	06-14-2004	Bayer Healthcare AG		
B45	WO 2004/055520	07-01-2004	One Way Liver Genomics, S.L.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C1	AHMED <i>et al.</i> , Serial Intravascular Ultrasound Assessment of the Efficacy of Intracoronary $\gamma$ -Radiation Therapy for Preventing Recurrence in Very Long, Diffuse, In-Stent Restenosis Lesions, <i>Circ.</i> , 104:856-859 (2001).		
	C2	AIELLO <i>et al.</i> , Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells In Mice, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22:443-449 (2002).		
	C3	ALLEN <i>et al.</i> , Enhanced Excretion of Urinary Leukotriene E <sub>4</sub> in Coronary Artery Disease and After Coronary Artery Bypass Surgery, <i>Coronary Artery Disease</i> , 4: 899-904 (1993).		
	C4	ALLEN <i>et al.</i> , Differential Leukotriene Constrictor Responses in Human Atherosclerotic Coronary Arteries, <i>Circulation</i> , 97:2406-2413 (1998).		
	C5	ANDRESOTTIR <i>et al.</i> , Fifteen Percent of Myocardial Infarctions and Coronary Revascularizations Explained by Family History Unrelated to Conventional Risk Factors, <i>European Heart Journal</i> , 23:1655-1663 (2002).		

Examiner Signature	/Jeanine Goldberg/	Date Considered	10/20/2008
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,674
				Filing Date	April 22, 2004
				First Named Inventor	Anna Helgadottir
				Art Unit	1634
				Examiner Name	Not Yet Assigned
Sheet	3	of	8	Attorney Docket Number	30847/2048-004

C6	ASKONAS <i>et al.</i> , Pharmacological Characterization of SC-57461A (3-[Methyl[3-[4-(Phenylmethyl)Phenoxy]Propyl]Amino]Propanoic Acid HCl), a Potent and Selective Inhibitor of Leukotriene A <sub>4</sub> Hydrolase I: In Vitro Studies, <i>JPET</i> , 300:577-582 (2002).
C7	BAKR <i>et al.</i> , 5-Lipoxygenase and Leukotriene A <sub>4</sub> Hydrolase Expression in Primary Nephrotic Syndrome, <i>Pediatr Nephrol</i> , 19:396-399 (2004).
C8	BARONE <i>et al.</i> , Time-Related Changes in Myeloperoxidase Activity and Leukotriene B <sub>4</sub> Receptor Binding Reflect Leukocyte Influx in Cerebral Focal Stroke, <i>Mol. Chem. Neuropathol.</i> , 24:13-30 (1995).
C9	BARTH, J., Which Tools are in your Cardiac Workshop? Carotid Ultrasound, Endothelial Function, and Magnetic Resonance Imaging, <i>Am. J. Cardiol.</i> , 87(suppl) 8A-14A (2001).
C10	BERMUDEZ <i>et al.</i> , Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors in Women, <i>Arterioscler Thromb Vasc Biol.</i> , 22:1668-1673 (2002).
C11	BIRKE <i>et al.</i> , In Vitro and in Vivo Pharmacological Characterization of BIIL 284, a Novel and Potent Leukotriene B <sub>4</sub> Receptor Antagonist, <i>JPET</i> , 297:458-466 (2001).
C12	BLACKIE <i>et al.</i> , The Identification of Clinical Candidate SB-480848: A Potent Inhibitor of Lipoprotein-Associated Phospholipase A <sub>2</sub> , <i>Bioorganic Med. Chem. Lett.</i> , 13:1067-1070 (2003).
C13	BLAKE <i>et al.</i> , C-Reactive Protein, Subclinical Atherosclerosis, and Risk of Cardiovascular Events, <i>Arterioscler. Thromb. Vasc Biol.</i> , 22:1512-1513 (2002).
C14	BLAKE <i>et al.</i> , Projected Life-Expectancy Gains With Statin Therapy for Individuals With Elevated C-Reactive Protein Levels, <i>JACC</i> , 40:49-55 (2002).
C15	BOYD <i>et al.</i> , N-1 Substituted Pyrimidin-4-Ones: Novel, Orally Active Inhibitors of Lipoprotein-Associated Phospholipase A <sub>2</sub> , <i>Bioorganic Med. Chem. Lett.</i> , 10:2557-2561 (2000).
C16	BRENNAN <i>et al.</i> , Prognostic Value of Myeloperoxidase in Patients with Chest Pain, <i>N. Eng J. Med.</i> , 349:1595-1604 (2003).
C17	BUFFON <i>et al.</i> , Widespread Coronary Inflammation in Unstable Angina, <i>N. Engl. J. Med.</i> , 1:5-12 (2002).
C18	BYRUM <i>et al.</i> , Determination of the Contribution of Cysteinyl Leukotrienes and Leukotriene B <sub>4</sub> in Acute Inflammatory Responses Using 5-Lipoxygenase- and Leukotriene A <sub>4</sub> Hydrolase-Deficient Mice, <i>J. Immunol.</i> , 163:6810-6819 (1999).
C19	CARRY <i>et al.</i> , Increased Urinary Leukotriene Excretion in Patients with Cardiac Ischemia; In vivo Evidence for 5-Lipoxygenase Activation, <i>Circulation</i> , 85: 232-236 (1992).
C20	CASLAKE <i>et al.</i> , Lipoprotein-Associated Phospholipase A <sub>2</sub> (Platelet-Activating Factor Acetylhydrolase) and Cardiovascular Disease, <i>Curr. Opin. Lipidol.</i> , 14:347-352 (2003).
C21	CHANG <i>et al.</i> , C-Reactive Protein Binds to Both Oxidized LDL and Apoptotic Cells Through Recognition of a Common Ligand: Phosphorylcholine of Oxidized Phospholipids, <i>PNAS</i> , 99:13043-13048 (2002).
C22	CHEN <i>et al.</i> , Leukotriene A <sub>4</sub> Hydrolase in Rat and Human Esophageal Adenocarcinomas and Inhibitory Effects of Bestatin, <i>J. of the Natl. Cancer Institute</i> , 95:1053-1060 (2003).
C23	COLLINS <i>et al.</i> , Effects of Cholesterol-Lowering with Simvastatin on Stroke and Other Major Vascular Events in 20 536 People with Cerebrovascular Disease or Other High-Risk Conditions, <i>Lancet</i> , 363:757-767 (2004).
C24	CYRUS <i>et al.</i> , Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Arterogenesis in Low-Density Lipoprotein Receptor-Deficient Mice, <i>Circ.</i> , 106:1282-1287 (2002).
C25	DAHLEN <i>et al.</i> , Inhibition of Allergen-Induced Airway Obstruction and Leukotriene Generation in Atopic Asthmatic Subjects by the Leukotriene Biosynthesis Inhibitor BAYx 10005, <i>Thorax</i> , 52: 342-347 (1997).
C26	DANESH <i>et al.</i> , C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease, <i>N. Engl. J. Med.</i> , 350:1387-1397 (2004).

Examiner Signature	/Jeanine Goldberg/	Date Considered	10/20/2008
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,674
				Filing Date	April 22, 2004
				First Named Inventor	Anna Helgadottir
				Art Unit	1634
				Examiner Name	Not Yet Assigned
Sheet	4	of	8	Attorney Docket Number	30847/2048-004

C27	DAVIDSON, M., Introduction: Utilization of Surrogate Markers of Atherosclerosis for the Clinical Development of Pharmaceutical Agents, <i>Am. J. Cardiol.</i> , 87(suppl): 1A-7A (2001).
C28	DE CATERINA et al., Leukotriene B <sub>4</sub> Production in Human Atherosclerotic Plaques, <i>Biomed. Biochim. Acta</i> , 47: S182-85 (1988).
C29	DEVILLIER et al., Leukotrienes, Leukotriene Receptor Antagonists and Leukotriene Synthesis Inhibitors in Asthma: An Update. Part II: Clinical Studies with Leukotriene Receptor Antagonists and Leukotriene Synthesis Inhibitors in Asthma, <i>Pharmacol. Res.</i> , 40:15-29 (1999).
C30	DOGGEN et al., C-Reactive Protein, Cardiovascular Risk Factors and the Association With Myocardial Infarction in Men, <i>J. Intern. Med.</i> , 248:406-414 (2000).
C31	DRAZEN et al., Pharmacogenetic Association Between ALOX5 Promoter Genotype and the Response to Anti-Asthma Treatment, <i>Nat. Genet.</i> , 22:168-170 (1999).
C32	DWYER et al., Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis, <i>N. Eng. J. Med.</i> , 350:29-37 (2004).
C33	EBERHARD et al., Leukotriene A <sub>4</sub> -Hydrolase Expression and Leukotriene B <sub>4</sub> Levels in Chronic Inflammation of Bacterial Origin; Immunohistochemistry and Reverse-Phase High-Performance Liquid Chromatography Analysis of Oral Mucosal Epithelium, <i>Virchows Arch</i> , 440:627-634 (2002).
C34	FAULER et al., Cardiovascular Effects of Leukotrienes, <i>Cardiovasc. Drugs Ther.</i> , 3:499-505 (1989).
C35	FELTENMARK et al., Diverse Expression of Cytosolic Phospholipase A <sub>2</sub> , 5-Lipoxygenase and Prostaglandin H Synthase 2 in Acute Pre-B-Lymphocytic Leukaemia Cells, <i>British J. of Haematology</i> , 90:585-594 (1995).
C36	FISCHER et al., Effect of a Novel 5-Lipoxygenase Activating Protein Inhibitor, BAYx 1005, on Asthma Induced by Cold Dry Air, <i>Thorax</i> , 52:1074-1077 (1997).
C37	FOLCIK et al., Lipoxygenase Contributes to the Oxidation of Lipids in Human Atherosclerotic Plaques, <i>J. Clin. Invest.</i> , 96:504-510 (1995).
C38	FOLCO et al., Leukotrienes in Cardiovascular Diseases, <i>Am. J. Respir. Crit. Care Med.</i> , 161:S112-S116 (2000).
C39	FRENETTE et al., Substituted Indoles as Potent and Orally Active 5-Lipoxygenase Activating Protein (Flap) Inhibitors, <i>Bioorg. Med. Chem. Lett.</i> , 9:2391-2396 (1999).
C40	FRIEDRICH et al., Mechanisms of Leukotriene B <sub>4</sub> - Triggered Monocyte Adhesion, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 23:1761 (2003).
C41	FUNK, C., Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology, <i>Science</i> , 294:1871-1875 (2001).
C42	FUNK et al., Molecular Cloning and Amino Acid Sequence of Leukotriene A <sub>4</sub> Hydrolase, <i>Proc. Natl. Acad. Sci.</i> , 84:6677-6681 (1987).
C43	GOMPERTZ et al., A Randomized, Placebo-Controlled Trial of a Leukotriene Synthesis Inhibitor in Patients with COPD, <i>Chest</i> , 122:289-94 (2002).
C44	HAGENAARS et al., Rationale and Design for the SARIS Trial; Effect of Statin on Atherosclerosis and Vascular Remodeling Assessed with Intravascular Sonography, <i>Cardiovasc. Drugs Ther.</i> , 15:339-343 (2001).
C45	HEINZMANN et al., Studies on Linkage and Association of Atopy with the Chromosomal Region 12q13-24, <i>Clin. Exp. Allergy</i> , 30:1554-1561 (2000).
C46	HELGADOTTIR et al., Familial Clustering of Myocardial Infarction in the Icelandic Population: Evidence for Genetic Components, <i>Am. J. of Human Gen.</i> , 84:A205: 1128 (1999).
C47	HELGADOTTIR et al., The Gene Encoding 5-Lipoxygenase Activating Protein Confers Risk of Myocardial Infarction and Stroke, <i>Nat. Genet.</i> , 36:233-239 (2004).
C48	IN et al., Naturally Occurring Mutations in the Human 5-Lipoxygenase Gene Promoter that Modify Transcription Factor Binding and Reporter Gene Transcription, <i>J. Clin. Invest.</i> , 99:1130-1137 (1997).

Examiner Signature	/Jeanine Goldberg/	Date Considered	10/20/2008
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,674
				Filing Date	April 22, 2004
				First Named Inventor	Anna Helgadottir
				Art Unit	1634
				Examiner Name	Not Yet Assigned
Sheet	5	of	8	Attorney Docket Number	30847/2048-004

C49	ISHIZAKA <i>et al.</i> , Increased Leukotriene A <sub>4</sub> Hydrolase Expression in the Heart of Angiotensin II-Induced Hypertensive Rat, <i>FEBS Letters</i> , 463:155-159 (1999).	
C50	JONSDOTTIR <i>et al.</i> , Incidence and Prevalence of Recognised and Unrecognised Myocardial Infarction in Women, <i>Eur. Heart J.</i> , 19:1011-1018 (1998).	
C51	KACHUR <i>et al.</i> , Pharmacological Characterization of SC-57461A (3-[Methyl[3-[4-(Phenylmethyl)Phenoxy]Propyl]Amino]Propanoic Acid HCl), a Potent and Selective Inhibitor of Leukotriene A <sub>4</sub> Hydrolase II: In Vivo Studies, <i>JPET</i> , 300:583-587 (2002).	
C52	KAISER <i>et al.</i> , Proteomics Applied to the Clinical Follow-up of Patients After Allogeneic Hematopoietic Stem Cell Transplantation, <i>Blood</i> , 104:340-349 (2004).	
C53	KANAYAMA <i>et al.</i> , A New Prostacyclin Analog, KP-10614, Inhibits Platelet-Polymorphonuclear Leukocyte Interaction and Limits Experimental Infarct Size in Rat Heart, <i>J. Pharmacol. Exp. Ther.</i> , 266:344-349 (1993).	
C54	KEANEY, JR. <i>et al.</i> , The Value of Inflammation for Predicting Unstable Angina, <i>N. Engl. J. Med.</i> , 347:55-57 (2002).	
C55	KOLASA <i>et al.</i> , Synthesis of Indolylalkoxyiminoalkylcarboxylates as Leukotriene Biosynthesis Inhibitors, <i>Bioorg. Med. Chem.</i> , 5:507-514 (1997).	
C56	KRISTJANSSON <i>et al.</i> , Improved One-Year Survival After Acute Myocardial Infarction in Iceland Between 1986 and 1996, <i>Cardiology</i> , 91:210-214 (1999).	
C57	KUHN <i>et al.</i> , Amino Acids Differences in the Deduced 5-Lipoxygenase Sequence of CAST Atherosclerosis-Resistance Mice Confer Impaired Activity when Introduced Into the Human Ortholog, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 23:1072-1076 (2003).	
C58	KURIBAYASHI <i>et al.</i> , Inhibitory Effects of a Phosphate Diester of $\alpha$ -Tocopherol and Ascorbic Acid (EPC-K <sub>1</sub> ) on Myocardial Infarction in Rats, <i>Int. J. Tiss. React.</i> , 18:73-79 (1996).	
C59	LAM <i>et al.</i> , Leukotriene C <sub>4</sub> Uses a Probenecid-Sensitive Export Carrier That Does Not Recognize Leukotriene B <sub>4</sub> , <i>PNAS USA</i> , 89:11598-11602 (1992).	
C60	LEHR <i>et al.</i> , Involvement of 5-Lipoxygenase Products in Cigarette Smoke-Induced Leukocyte/Endothelium Interaction in Hamsters, <i>Int. J. Microcirc.: Clin. Exp.</i> , 12:61-73 (1993).	
C61	MAGEE <i>et al.</i> , An Integrated Pharmacokinetic/Pharmacodynamic (PK/PD) Model for SB-480848 Inhibition of Plasma Lipoprotein-Associated Phospholipase A <sub>2</sub> (LP-PLA <sub>2</sub> ) Enzyme Activity in Human, <i>American Society for Clinical Pharm. and Ther. Abstract PIII-87</i> (2003).	
C62	MEHRABIAN, <i>et al.</i> , Identification of 5-Lipoxygenase as a Major Gene Contributing to Atherosclerosis Susceptibility in Mice, <i>Circ. Res.</i> , 91:120-126 (2002).	
C63	MENEGATTI <i>et al.</i> , Gene Expression of 5-Lipoxygenase and LTA <sub>4</sub> Hydrolase in Renal Tissue of Nephrotic Syndrome Patients, <i>Clin. Exp. Immunol.</i> , 116:347-353 (1999).	
C64	OKANO-MITANI <i>et al.</i> , Leukotriene A <sub>4</sub> Hydrolase in Peripheral Leukocytes of Patients with Atopic Dermatitis, <i>Arch Dermatol Res.</i> , 288:168-172 (1996).	
C65	MONTERO <i>et al.</i> , LTA <sub>4</sub> Hydrolase Expression During Glomerular Inflammation: Correlation of Immunohistochemical Localization with Cytokine Regulation, <i>Adv. Exp. Med. Biol.</i> , 449-454 (1999).	
C66	MUELLER <i>et al.</i> , Leukotriene A <sub>4</sub> Hydrolase, Mutation of Tyrosine 378 Allows Conversion of Leukotriene A <sub>4</sub> into an Isomer of Leukotriene B <sub>4</sub> , <i>J. Biol. Chem.</i> , 271:24345-24348 (1996).	
C67	MULLER-PEDDINGHAUS <i>et al.</i> , BAY X1005, A New Inhibitor of Leukotriene Synthesis: <i>in Vivo</i> Inflammation Pharmacology and Pharmacokinetics, <i>J. Pharmacol. Exp. Ther.</i> , 267:51-57 (1993).	
C68	MULLER-PEDDINGHAUS <i>et al.</i> , BAY X1005, A New Selective Inhibitor of Leukotriene Synthesis: Pharmacology and Pharmacokinetics, <i>J. Lipid. Mediat.</i> , 6:245-248 (1993).	
C69	MULLER-PEDDINGHAUS, R., Potential Anti-Inflammatory Effects of 5-Lipoxygenase Inhibition -- Exemplified by the Leukotriene Synthesis Inhibitor Bay X 1005, <i>J. Phys. Pharmacol.</i> , 48:529-536 (1997).	
C70	NISSSEN, S., Coronary Angiography and Intravascular Ultrasound, <i>Am. J. Cardiol.</i> , 87(suppl):15A-20A (2001).	

Examiner Signature	/Jeanine Goldberg/	Date Considered	10/20/2008
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,674
				Filing Date	April 22, 2004
				First Named Inventor	Anna Helgadottir
				Art Unit	1634
				Examiner Name	Not Yet Assigned
Sheet	6	of	8	Attorney Docket Number	30847/2048-004

C71	OESTVANG <i>et al.</i> , Role of Secretory and Cystolic Phospholipase A <sub>2</sub> Enzymes in Lysophosphatidylcholine-Stimulated Monocyte Arachidonic Acid Release, <i>FEBS Lett.</i> , 555:257-262 (2003).
C72	OZAKI <i>et al.</i> , Functional SNPs in the Lymphotoxin- $\alpha$ Gene that are Associated with Susceptibility to Myocardial Infarction, <i>Nat. Genet.</i> , Published online: 11 November 2002, doi:10.1038/ng1047, pp. 1-5 (2002).
C73	PACKARD, <i>et al.</i> , Lipoprotein-Associated Phospholipase A <sub>2</sub> as an Independent Predictor of Coronary Heart Disease, <i>N. Eng. J. Med.</i> , 343:1148-1155 (2000).
C74	PATERNITI, JR., J., Investigational New Drug Applications: The Role of the Preclinical Dossier, <i>Am. J. Cardiol.</i> , 81(suppl):10F-12F (1998).
C75	PENNING <i>et al.</i> , Inhibitors of Leukotriene A <sub>4</sub> (LTA <sub>4</sub> ) Hydrolase as Potential Anti-Inflammatory Agents, <i>Current Pharmaceutical Design</i> , 7:163-179 (2001).
C76	PENNING <i>et al.</i> , Pyrrolidine and Piperidine Analogues of SC-57461A as Potent, Orally Active Inhibitors of Leukotriene A <sub>4</sub> Hydrolase, <i>Bioorg. Med. Chem. Lett.</i> , 12:3383-3386 (2002).
C77	PENNING <i>et al.</i> , Structure-Activity Relationship Studies on 1-[2(4-Phenylphenoxy)Ethyl]Pyrrolidine (SC-22716), a Potent Inhibitor of Leukotriene A <sub>4</sub> (LTA <sub>4</sub> ) Hydrolase, <i>J. Med. Chem.</i> , 43:721-735 (2000).
C78	PENNING <i>et al.</i> , Synthesis of Imidazopyridines and Purines as Potent Inhibitors of Leukotriene A <sub>4</sub> Hydrolase, <i>Bioorg. Med. Chem. Lett.</i> , 13:1137-1139 (2003).
C79	PENNING <i>et al.</i> , Synthesis of Potent Leukotriene A <sub>4</sub> Hydrolase Inhibitors. Identification of 3-[Methyl[3-[4-(Phenylmethyl)Phenoxy]Propyl]Amino]Propanoic Acid, <i>J. Med. Chem.</i> , 45:3482-3490 (2002).
C80	PITT <i>et al.</i> , Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease, <i>N. Eng. J. Med.</i> , 341:70-76 (1999).
C81	POTEMPA <i>et al.</i> , Stimulatory Effects of the C-Reactive Protein Subunit on Monocyte Function, Including Release of IL-1, <i>Biol. Fluids</i> 34: 287-290. 1986.
C82	RADMARK, O., 5-Lipoxygenase-Derived Leukotrienes. Mediators Also of Atherosclerotic Inflammation, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 23:1140-1142 (2003).
C83	RAGGI, P., Coronary Calcium on Electron Beam Tomography Imaging as a Surrogate Marker of Coronary Artery Disease, <i>Am. J. Cardiol.</i> , 87(suppl):27A-34A (2001).
C84	RETTERSTOL <i>et al.</i> , C-Reactive Protein Predicts Death in Patients With Previous Premature Myocardial Infarction - A 10 Year Follow-Up Study, <i>Atherosclerosis</i> , 160:433-440 (2002).
C85	RIDKER <i>et al.</i> , Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events, <i>N. Engl. J. Med.</i> , 347:1557-1565 (2002).
C86	RIDKER <i>et al.</i> , C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women, <i>N. Engl. J. Med.</i> , 342:836-843 (2000).
C87	RIDKER <i>et al.</i> , Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels, <i>Circulation</i> , 98:839-844 (1998).
C88	ROSENFELD, M., Leukocyte Recruitment Into Developing Atherosclerotic Lesions. The Complex Interaction Between Multiple Molecules Keeps Getting More Complex, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22:361-363 (2002).
C89	ROSS, R., Atherosclerosis -- An Inflammatory Disease, <i>N. Eng. J. Med.</i> , 340:115-126 (1999).
C90	ROSSONI <i>et al.</i> , Myocardial Protection by the Leukotriene Synthesis Inhibitor BAY X1005: Importance of Transcellular Biosynthesis of Cysteinyl-Leukotrienes, <i>J. Pharmacol. Exp. Therapeutics</i> , 276:335-341 (1996).
C91	RYBINA <i>et al.</i> , Alteration of Human Leukotriene A <sub>4</sub> Hydrolase Activity After Site-Directed Mutagenesis: Serine-415 is a Regulatory Residue, <i>Biochim. Biophys. ACTA</i> , 1438:199-203 (1999).
C92	SALA <i>et al.</i> , Leukotrienes: Lipid Bioeffectors of Inflammatory Reactions, <i>Biochemistry</i> , 63:84-92 (1998).

Examiner Signature	/Jeanine Goldberg/	Date Considered	10/20/2008
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,674
				Filing Date	April 22, 2004
				First Named Inventor	Anna Helgadottir
				Art Unit	1634
				Examiner Name	Not Yet Assigned
Sheet	7	of	8	Attorney Docket Number	30847/2048-004

C93	SALA <i>et al.</i> , Monoclonal Anti-CD18 Antibody Prevents Transcellular Biosynthesis of Cysteinyl Leukotrienes In Vitro and In Vivo and Protects Against Leukotriene-Dependent Increase in Coronary Vascular Resistance and Myocardial Stiffness, <i>Circulation</i> , 101:1436-1440 (2000).
C94	SAMPSON, Leukotrienes in Cardiovascular Disease, <i>Clinical and Experimental Allergy Review</i> , 1:170-174 (2001).
C95	SHEPHERD, J., Economics of Lipid Lowering in Primary Prevention: Lessons from the West of Scotland Coronary Prevention Study, <i>Am. J. Cardiol.</i> , 87 (suppl):19B-22B (2001).
C96	SHOWELL <i>et al.</i> , The Preclinical Pharmacological Profile of the Potent and Selective Leukotriene B <sub>4</sub> Antagonist CP-195543, <i>JPET</i> , 285:946-954 (1998).
C97	SIGURDSSON <i>et al.</i> , Long-Term Prognosis of Different Forms of Coronary Heart Disease: The Reykjavik Study, <i>Int. J. Epidemiol.</i> , 24:58-68 (1995).
C98	SIGURDSSON <i>et al.</i> , Silent ST-T Changes in an Epidemiologic Cohort Study -- A Marker of Hypertension or Coronary Heart Disease, or Both: The Reykjavik Study, <i>J. Am. Coll. Cardiol.</i> , 27:1140-1147 (1996).
C99	SMILDE <i>et al.</i> , Effect of Aggressive Versus Conventional Lipid Lowering on Atherosclerosis Progression in Familial Hypercholesterolaemia (ASAP): A Prospective, Randomised, Double-Blind Trial, <i>Lancet</i> , 357:577-581 (2001).
C100	SPANBROEK <i>et al.</i> , Expanding Expression of the 5-Lipoxygenase Pathway within the arterial Wall During Human Atherogenesis, <i>PNAS USA</i> 100:1238-1243 (2003).
C101	STEIN E., Laboratory Surrogates for Anti-Atherosclerotic Drug Development, <i>Am. J. Cardio.</i> , 87:21A-26A (2001).
C102	STEINHILBER, D., 5-Lipoxygenase: A Target for Antiinflammatory Drugs Revisited, <i>Curr. Med. Chem.</i> , 5:71-85 (1999).
C103	SUBBARAO <i>et al.</i> , Role of Leukotriene B <sub>4</sub> Receptors in the Development of Atherosclerosis: Potential Mechanisms, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 24:369 (2003).
C104	TAKASE, Change of Plasma Leukotriene C <sub>4</sub> During Myocardial Ischemia in Humans, <i>Clin. Cardiol.</i> , 19:198-204 (1996).
C105	TAUBES G., Does Inflammation Cut to the Heart of the Matter?, <i>Science</i> , 296:242-245 (2002).
C106	THUNNISSEN <i>et al.</i> , Crystal Structure of Human Leukotriene A <sub>4</sub> Hydrolase, a Bifunctional Enzyme in Inflammation, <i>Nat. Struct. Biol.</i> , 8:131-135 (2001).
C107	THUNNISSEN <i>et al.</i> , Crystal Structures of Leukotriene A <sub>4</sub> Hydrolase in Complex with Captopril and Two Competitive Tight-Binding Inhibitors, <i>FASEB Journal</i> , 16:1648-1650 (2002).
C108	TRACY, Inflammation in Cardiovascular Disease. Cart, Horse or Both Revisited, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22:1514-1515 (2002).
C109	TSELEPIS <i>et al.</i> , Inflammation, Bioactive Lipids and Atherosclerosis: Potential Roles of a Lipoprotein-Associated Phospholipase A <sub>2</sub> , Platelet Activating Factor-Acetylhydrolase, <i>Artheroscler. Suppl.</i> , 3:57-68 (2002).
C110	VERMA <i>et al.</i> , A Self-Fulfilling Prophecy. C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis, <i>Circulation</i> , 106:913-919 (2002).
C111	WALTER <i>et al.</i> , Benefits of Immediate Initiation of Statin Therapy Following Successful Coronary Stent Implantation in Patients with Stable and Unstable Angina Pectoris and Q-Wave Acute Myocardial Infarction, <i>Am. J. Cardiol.</i> , 89:1-6 (2002).
C112	WANG <i>et al.</i> , Association of C-Reactive Protein With Carotid Atherosclerosis in Men and Women: The Framingham Heart Study, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22:1662-1667 (2002).
C113	WATERS <i>et al.</i> , Effects of Atorvastatin on Stroke in Patients with Unstable Angina or Non-Q-Wave Myocardial Infarction. A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy, <i>Circulation</i> , 106:1690-1695 (2002).
C114	WETTERHOLM <i>et al.</i> , Leukotriene A <sub>4</sub> Hydrolase: Abrogation of the Peptidase Activity by Mutation of Glutamic Acid-296, <i>Proc. Natl. Acad. Sci.</i> , 89:9141-9145, (1992).

Examiner Signature	/Jeanine Goldberg/	Date Considered	10/20/2008
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/829,674
				Filing Date	April 22, 2004
				First Named Inventor	Anna Helgadottir
				Art Unit	1634
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	30847/2048-004
Sheet	8	of	8		

C115	WILLERSON <i>et al.</i> , Protection of the Myocardium During Myocardial Infarction: Pharmacologic Protection During Thrombolytic Therapy, <i>Am. J. Cardio.</i> , 65: 35 I-41 I (1990).	
C116	YAMADA <i>et al.</i> , Prediction of the Risk of Myocardial Infarction from Polymorphisms in Candidate Genes, <i>N. Eng. J. Med.</i> , 347:1916-1923 (2002).	
C117	YOKOMIZO <i>et al.</i> , cDNA Cloning, Expression, and Mutagenesis Study of Leukotriene B <sub>4</sub> 12-Hydroxydehydrogenase, <i>J. Biol. Chem.</i> , 271: 2844-2850 (1996).	
C118	ZHANG <i>et al.</i> , Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease, <i>JAMA</i> , 286:2136-2142 (2001).	
C119	ZHAO <i>et al.</i> , The 5-Lipoxygenase Pathway Promotes Pathogenesis of Hyperlipidemia-Dependent Aortic Aneurysm, <i>Nat. Med.</i> , 10:966-973 (2004).	
C120	The SNP Consortium Ltd., SNP Report for TSC0806241, Gene sequence, (rs1323898), October 10, 2000.	
C121	International Search Report for PCT/US2003/32805 dated January 14, 2005.	
C122	International Search Report for PCT/US2004/030582 dated February 28, 2005	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jeanine Goldberg/	Date Considered	10/20/2008
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/